Calculate real-time PCR amplification efficiency from standard curve slopes (E = 10^(-1/slope) - 1), evaluate R² linearity, analyze Ct replicate statistics, and compute Pfaffl relative quantification fold changes.
At 100% efficiency ($E = 2.0$), the quantity of target amplicons exactly doubles ($2^1 = 2$) every thermal cycle, producing a 3.322 cycle shift per 10-fold serial dilution ($2^{3.322} \approx 10$).
In quantitative real-time PCR (qPCR), amplification follows exponential kinetics where the quantity of target amplicon doubles with each thermal cycle under ideal conditions. The accumulation of PCR product is described by the fundamental exponential equation:
Where N_n is the number of amplicon molecules at cycle n, N_0 is the initial starting copy number, and E is the fractional amplification efficiency ($0.0 \le E \le 1.0$). At theoretical 100% efficiency ($E = 1.0$), the base term $(1 + E) = 2.0$, representing exact cycle-to-cycle DNA doubling.
When performing a serial dilution series across known template concentrations, plotting the threshold cycle (Ct or Cq) on the Y-axis against the common logarithm ($\log_{10}$) of starting template quantity produces a linear regression line: Ct = m × log₁₀(Quantity) + b.
To express as a percentage: % Efficiency = (10^(-1/m) - 1) × 100.
In a 10-fold serial dilution, 100% doubling requires $\log_2(10) \approx 3.322$ cycles between each 10-fold step.
Assays falling outside the MIQE-accepted 90%–110% range indicate experimental or biochemical artifacts:
Apparent "super-efficiency" is physiologically impossible. It almost always signifies PCR inhibitors (e.g. ethanol, phenol, humic acids, or high salts) present in the concentrated standard curve points, which artificially delay high-concentration Ct values. As template is diluted, inhibitors dilute out, causing low-concentration samples to amplify faster than expected.
Poor efficiency indicates sub-optimal annealing temperatures, primer secondary structure (strong hairpins or self-dimers), degraded master mix, sub-optimal $Mg^{2+}$ concentration, or overly long amplicon lengths (>150 bp).
The widely used Livak $2^{-\Delta\Delta Ct}$ comparative method assumes that both target and reference housekeeping genes amplify with identical 100% efficiencies ($E = 2.0$). In practice, primer pairs rarely have identical amplification rates. The Pfaffl mathematical model (2001) calculates exact relative fold changes by incorporating individual assay efficiencies:
Even a minor 5% efficiency discrepancy between target ($E=1.92$) and reference ($E=2.02$) over a 4-cycle $\Delta Ct$ introduces over 25% to 40% quantification error if left uncorrected by the Livak method.
The mathematical formula to calculate amplification efficiency (E) from the linear regression slope (m) of a standard curve (plotting Ct versus log10 template concentration) is E = 10^(-1/m) - 1. To express this as a percentage, multiply by 100: % Efficiency = (10^(-1/m) - 1) × 100. The amplification factor per cycle is given by 10^(-1/m), where a value of 2.0 corresponds to an exact 100% doubling of DNA product every thermal cycle.
According to MIQE (Minimum Information for Publication of Quantitative Real-Time PCR Experiments) guidelines, an acceptable qPCR assay efficiency falls between 90% and 110%, which corresponds to a standard curve slope between -3.58 and -3.10. An ideal slope of -3.322 represents exactly 100% efficiency, meaning that every PCR cycle results in a theoretical 2-fold (100%) doubling of target cDNA/DNA amplicons.
Efficiencies below 90% (slope < -3.58) are typically caused by sub-optimal annealing temperatures, poorly designed primer pairs with secondary structures (hairpins/dimers), sub-optimal Mg2+ or dNTP concentrations, or degraded reagents. Efficiencies above 110% (slope > -3.10) almost always indicate PCR inhibition in high-concentration standard curve samples (e.g. carryover of ethanol, phenol, salts, or heparin from RNA/DNA extraction) or non-specific amplification/primer dimers at low template dilutions that artificially depress Ct values.
The coefficient of determination (R²) quantifies the linearity and goodness-of-fit of the standard curve data. An R² ≥ 0.98 (or R² ≥ 0.99 for publication-grade diagnostic assays) demonstrates high pipetting precision, minimal technical replicate variance, and uniform amplification kinetics across the entire dynamic range. An R² below 0.98 suggests serial dilution pipetting inconsistencies, improper mixing, or extreme outlier replicates.
The Livak 2^(-ΔΔCt) method assumes that both the target gene and reference/housekeeping gene amplify with identical, 100% efficiencies (E = 2.0). However, if primer efficiencies differ (e.g. Target = 92% and Reference = 104%), the Livak formula introduces significant quantification error. The Pfaffl method mathematically corrects for differing efficiencies using the ratio: Ratio = [(E_target)^(ΔCt_target (control - sample))] / [(E_ref)^(ΔCt_ref (control - sample))], providing true, unbiased relative gene expression fold changes.
The MIQE guidelines require researchers to report: (1) The standard curve slope, Y-intercept, and R² value; (2) The calculated amplification efficiency (E or %E); (3) The linear dynamic range (span of orders of magnitude); (4) The limit of detection (LOD) and quantification (LOQ); and (5) Evidence that both target and reference assays have been evaluated for efficiency before applying comparative relative quantification methods.
